Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCEH1 | Q6PIU2 | 13/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL829483 | 0.86 | NCEH1 (0.66) | NCEH1LMNARXFP1NPC1MAPT | |
| SCHEMBL829421 | 0.76 | NCEH1 (0.53) | NCEH1LMNARXFP1KMT2ASMN1; SMN2 | |
| SCHEMBL830131 | 0.72 | SMN1; SMN2 (0.72) | NCEH1LMNANPSR1RXFP1KMT2A | |
| SCHEMBL27861350 | 0.70 | ACHE (0.46) | KMT2ANPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL4190695 | 0.69 | ABCC1 (0.60) | LMNAKMT2ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL3019686 | 0.66 | NCEH1 (0.58) | NCEH1LMNARXFP1KMT2APOLB | |
| SCHEMBL829714 | 0.65 | KMT2A (0.69) | NCEH1LMNANPSR1RXFP1KMT2A | |
| SCHEMBL830202 | 0.65 | NCEH1 (1.00) | NCEH1LMNANPC1MAPTRAB9A | |
| SCHEMBL304311 | 0.64 | ATM (0.46) | KMT2APOLBNPC1MAPTRAB9A | |
| SCHEMBL8518782 | 0.63 | NCEH1 (0.55) | NCEH1LMNARXFP1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143257-B2 | inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester | PTC THERAPEUTICS, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20080261956-A1 | Substituted Phenols as Active Agents Inhibiting Vegf Production | PTC THERAPEUTICS, INC. | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261956-A1 | Substituted Phenols as Active Agents Inhibiting Vegf Production | VEGFA, FLT4, FLT1 | NCEH1 3211/4885LMNA 4326/4885NPSR1 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.